The Impact of Weight Loss Drugs on Spending Habits
Weight loss medications are significantly influencing consumer spending patterns, with a recent study revealing that some users are adjusting their budgets. While some individuals are reducing their grocery expenses, they are investing more in beauty products and self-care items.
According to Federal Health Minister Mark Butler, over 400,000 Australians are currently using Glucagon-Like Peptide-1 (GLP-1) weight loss drugs. These medications can be quite expensive, with annual costs reaching up to $5000, depending on the medication's strength and eligibility under the Pharmaceutical Benefit Scheme.
Market research company Circana has been tracking the spending habits of Australian households with GLP-1 users and has conducted similar research in the US. Their findings indicate a 2% decrease in food and beverage spending during the 6-12 month period of medication use.
However, this trend is short-lived, as spending returns to normal once individuals discontinue the medication. Circana Insights Director Daniel Bone explains that GLP-1 users already tend to spend more on food and beverages.
Bone highlights that 46% of Australians are purchasing products to manage their weight, either for themselves or others in their household. These individuals spend 10% more in Australian pharmacy retail and maintain similar grocery spending as the general population.
The US research also uncovered that GLP-1 users tend to allocate more funds towards self-care and beauty products. Some users report lifestyle and self-care improvements while on GLP-1 medications, which may contribute to increased spending in these categories.
Bone suggests that the growing focus on weight loss through GLP-1 medications is driving the popularity of protein-forward products. Circana's data shows a 40% year-on-year growth in protein-led products within the Australian grocery industry, which is six times higher than the overall food and grocery sector.
This trend is attributed to GLP-1 users actively seeking protein-rich options, as they are aware that weight loss medications can lead to muscle mass loss. Bone predicts that the availability of weight loss drugs in pill form in Australia will further boost these trends in beauty, pharmacy, grocery, food, and beverage.
This shift presents both opportunities and challenges for food manufacturers. Bone emphasizes the potential for premiumization, where functional health products with higher fiber, nutrient density, smaller portions, or protein content can attract consumers willing to pay a premium for these benefits.
